These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30667081)

  • 41. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing.
    Zhao Y; Zhang CL; Zeng BF; Wu XS; Gao TT; Oda Y
    Biochem Biophys Res Commun; 2009 Dec; 390(3):642-7. PubMed ID: 19818735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Germline TP53 variants and susceptibility to osteosarcoma.
    Mirabello L; Yeager M; Mai PL; Gastier-Foster JM; Gorlick R; Khanna C; Patiño-Garcia A; Sierrasesúmaga L; Lecanda F; Andrulis IL; Wunder JS; Gokgoz N; Barkauskas DA; Zhang X; Vogt A; Jones K; Boland JF; Chanock SJ; Savage SA
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25896519
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
    Cui B; Yang Q; Guan H; Shi B; Hou P; Ji M
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E962-70. PubMed ID: 24512488
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
    Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting hedgehog-GLI-2 pathway in osteosarcoma.
    Yang W; Liu X; Choy E; Mankin H; Hornicek FJ; Duan Z
    J Orthop Res; 2013 Mar; 31(3):502-9. PubMed ID: 22968906
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.
    van der Ent W; Jochemsen AG; Teunisse AF; Krens SF; Szuhai K; Spaink HP; Hogendoorn PC; Snaar-Jagalska BE
    J Pathol; 2014 Aug; 233(4):415-24. PubMed ID: 24974828
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
    Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
    Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MicroRNA-133a Inhibits Osteosarcoma Cells Proliferation and Invasion via Targeting IGF-1R.
    Chen G; Fang T; Huang Z; Qi Y; Du S; Di T; Lei Z; Zhang X; Yan W
    Cell Physiol Biochem; 2016; 38(2):598-608. PubMed ID: 26845446
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-cancer activity of trans-chalcone in osteosarcoma: Involvement of Sp1 and p53.
    Silva G; Marins M; Fachin AL; Lee SH; Baek SJ
    Mol Carcinog; 2016 Oct; 55(10):1438-48. PubMed ID: 26294168
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oridonin synergizes with Nutlin-3 in osteosarcoma cells by modulating the levels of multiple Bcl-2 family proteins.
    Wang XH; Zhang SF; Bao JT; Liu FY
    Tumour Biol; 2017 Jun; 39(6):1010428317701638. PubMed ID: 28618955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preliminary Application of Precision Genomic Medicine Detecting Gene Variation in Patients with Multifocal Osteosarcoma.
    Zhang HQ; Li MH; Gao P; Lan PH; Fan B; Xiao X; Lu YJ; Chen GJ; Wang Z
    Orthop Surg; 2016 May; 8(2):129-38. PubMed ID: 27384721
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential.
    Sun R; Shen J; Gao Y; Zhou Y; Yu Z; Hornicek F; Kan Q; Duan Z
    Oncotarget; 2016 Jun; 7(25):38333-38346. PubMed ID: 27223261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.
    Sevelda F; Mayr L; Kubista B; Lötsch D; van Schoonhoven S; Windhager R; Pirker C; Micksche M; Berger W
    J Exp Clin Cancer Res; 2015 Nov; 34():134. PubMed ID: 26526352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic and epigenetic alterations of the cell cycle regulators and tumor suppressor genes in pediatric osteosarcomas.
    Patiño-García A; Piñeiro ES; Díez MZ; Iturriagagoitia LG; Klüssmann FA; Ariznabarreta LS
    J Pediatr Hematol Oncol; 2003 May; 25(5):362-7. PubMed ID: 12759621
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
    Mizuarai S; Yamanaka K; Kotani H
    Cancer Res; 2006 Jun; 66(12):6319-26. PubMed ID: 16778209
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy.
    Lee YS; Choi JY; Lee J; Shim DM; Kim J; Park WY; Nam DH; Seo SW
    Tumour Biol; 2018 Aug; 40(8):1010428318794217. PubMed ID: 30124118
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
    Engert F; Kovac M; Baumhoer D; Nathrath M; Fulda S
    Oncotarget; 2017 Jul; 8(30):48794-48806. PubMed ID: 27447864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients.
    Patiño-García A; Sierrasesúmaga L
    Cancer Genet Cytogenet; 1997 Oct; 98(1):50-5. PubMed ID: 9309118
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and biological significance of PIM1 kinase in osteosarcoma.
    Liao Y; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
    J Orthop Res; 2016 Jul; 34(7):1185-94. PubMed ID: 26687194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.